Faldaprevir clinical trials
Also written BI 201335.
Includes 6 studies of Faldaprevir sodium.
How each study uses faldaprevir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2012 (11)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 5 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 7 |
| 2012 | 11 |
| 2013 | 5 |
| 2016 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 38 · Other 0
Boehringer Ingelheim (37) · Trek Therapeutics, PBC (1)
Often tested with
Tested in the same studies.
Deleobuvir (6) · Ribavirin (5) · Deleobuvir sodium (2) · Peginterferon alfa-2a (2) · TD-6450 (1) · Tenofovir (1) · Tolbutamide (1) · Tacrolimus (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Studies
Open first, then newest update. How each study uses faldaprevir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 38
- Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -ExperiencedCompletedPhase 1Boehringer IngelheimNCT00793793Written as BI201335How we know
- A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus InfectionCompletedPhase 2Trek Therapeutics, PBCNCT02716428Written as FaldaprevirHow we know
- Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)CompletedPhase 3Boehringer IngelheimNCT01399619Written as BI201335How we know
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)CompletedPhase 3Boehringer IngelheimNCT01358864Written as BI 201335How we know
- A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedPhase 3Boehringer IngelheimNCT01330316Written as BI 201335How we know
- Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected PatientsCompletedPhase 1Boehringer IngelheimNCT01525628Written as BI 201335How we know
- Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or TacrolimusCompletedPhase 1Boehringer IngelheimNCT02016625Written as FaldaprevirHow we know
- This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis CCompletedPhase 2Boehringer IngelheimNCT01528735Written as BI 201335 NAHow we know
- Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female SubjectsCompletedPhase 1Boehringer IngelheimNCT01737996Written as BI 207127 + faldaprevirHow we know
- Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2CompletedPhase 3Boehringer IngelheimNCT01728324Written as Faldaprevir: 24-week treatmentHow we know
- Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 InfectionCompletedPhase 2Boehringer IngelheimNCT01132313Written as BI 201335How we know
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedPhase 3Boehringer IngelheimNCT01297270Written as BI201335How we know
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)CompletedPhase 3Boehringer IngelheimNCT01343888Written as BI 201335How we know
- Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)CompletedPhase 2Boehringer IngelheimNCT00984620Written as BI 201335How we know
- Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver CirrhosisCompletedPhase 1Boehringer IngelheimNCT01909778Written as BI 201335How we know
- Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination TrialCompletedPhase 3Boehringer IngelheimNCT01579474Written as BI 201335 high doseHow we know
- Investigation of Faldaprevir Effect on Pharmacokinetics of RaltegravirCompletedPhase 1Boehringer IngelheimNCT01785160Written as FaldaprevirHow we know
- Drug-drug Interaction of BI 201335 and MicrogynonCompletedPhase 1Boehringer IngelheimNCT01570244Written as BI 201335How we know
- Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/NaloxoneCompletedPhase 1Boehringer IngelheimNCT01637922Written as BI 201335How we know
- Pharmacokinetics of Faldaprevir of Soft CapsuleCompletedPhase 1Boehringer IngelheimNCT01821937Written as faldaprevir(high dose)How we know
See all 38 studies that test faldaprevir →
Given beside what is tested · 10 — faldaprevir is usual care or a partner of the new treatment
- A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus InfectionCompletedPhase 2Trek Therapeutics, PBCNCT02593162Written as FaldaprevirHow we know
- IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1CompletedPhase 3Boehringer IngelheimNCT01732796Written as BI 201335 (Faldaprevir)How we know
- Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.CompletedPhase 1Boehringer IngelheimNCT01965431Written as FaldaprevirHow we know
- Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired PatientsTerminatedPhase 1Boehringer IngelheimNCT01957657Written as faldaprevirHow we know
- Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and LevonorgestrelTerminatedPhase 1Boehringer IngelheimNCT01941615Written as faldaprevirHow we know
- Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis CCompletedPhase 2Presidio Pharmaceuticals, Inc.NCT01859962Written as FaldaprevirHow we know
- BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3CompletedPhase 2Boehringer IngelheimNCT01830127Written as FaldaprevirHow we know
- Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)CompletedPhase 2Boehringer IngelheimNCT00774397Written as BI 201335 NA 240 mg QD / LIHow we know
- Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy VolunteersCompletedPhase 1Boehringer IngelheimNCT02182375Written as BI 201335 NAHow we know
- Open Label Trial to Compare BI 207127 to Telaprevir in HCV PatientsWithdrawnPhase 3Boehringer IngelheimNCT01858961Written as BI 201335How we know
Codes
What other systems call faldaprevir · ClinicalTrials.gg INT005710
- MeSH (NLM) C552340faldaprevirOne source NLM
- UNII (FDA) 958X4J301AFALDAPREVIRConfirmed FDA, NLM, Wikidata
- Wikidata Q15408404faldaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C171746FaldaprevirOne source FDA
- DrugBank DB11808One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C552340 | faldaprevir | One source NLM |
| UNII (FDA) | 958X4J301A | FALDAPREVIR | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q15408404 | faldaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C171746 | Faldaprevir | One source FDA |
| DrugBank | DB11808 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.